Amgen's Q3 earnings call highlighted strong performance across the portfolio, exceeding expectations in several key areas.  Positive Phase 3 results, ongoing commercial success, and a raised 2014 guidance suggest a positive outlook.  Management's emphasis on biosimilar and pipeline developments, combined with cost-cutting measures, point to sustained growth, indicating a potentially bullish short-term outlook.
[1]
